FULGENT GENETICS, INC. Cash and Cash Equivalents
FULGENT GENETICS, INC. (FLGT) had Cash and Cash Equivalents of $26.30 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-30
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $26.30M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $23.40M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $50.19M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $117.64M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $26.30M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $23.40M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $50.19M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $117.64M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $87.88M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $67.28M 10-Q · filed 2026-05-01 |
| 2024-12-31 | $55.14M 10-K · filed 2026-02-27 |
| 2024-09-30 | $58.04M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $65.11M 10-Q · filed 2025-08-01 |
| 2024-03-31 | $54.68M 10-Q · filed 2025-05-02 |
| 2023-12-31 | $97.47M 10-K · filed 2026-02-27 |
| 2023-09-30 | $84.08M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $58.35M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $66.17M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $79.51M 10-K · filed 2025-02-28 |
| 2022-09-30 | $168.77M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $138.78M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $353.07M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $164.89M 10-K · filed 2023-02-28 |
| 2021-09-30 | $214.88M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $100.46M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $151.46M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $87.43M 10-K · filed 2022-02-28 |
| 2020-09-30 | $53.03M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $2.43M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $9.30M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $11.96M 10-K · filed 2021-03-08 |
| 2019-09-30 | $20.52M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $9.16M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $5.29M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $6.74M 10-K · filed 2020-03-13 |
| 2018-09-30 | $8.49M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $3.65M 10-Q · filed 2019-08-12 |
| 2018-03-31 | $5.27M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $6.49M 10-Q · filed 2019-08-12 |
| 2017-09-30 | $9.48M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $11.47M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $6.73M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $7.90M 10-K · filed 2018-03-20 |
| 2015-12-31 | $489.00K 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |